Maud Eijkenboom | Managing Director
Lixa

Maud is Managing Director and co-founder for the Lixa group of companies, developing resistance breakers and antibiofilm agents with a mission to solve AMR for anyone, anything, anywhere. As mother of an AMR survivor, she is passionate about the patient voice and developing fit-for-purpose solutions to the AMR problem across sectors. She is an international life sciences business builder with close to 30 years’ experience in multinational, listed, private and spin-out companies in therapeutic, medtech, animal health, cosmetic and consumer healthcare markets. Previous corporate and executive roles at Bayer Healthcare, Netura, Accelerating Australia and various listed entities. PhD in Neurobiology and MSc in Psychology.